Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR)

https://doi.org/10.20996/1819-6446-2010-6-6-796-802

Full Text:

Abstract

Aim. To compare the antiplatelet efficacy of the original and generic enterosoluble tableted acetylsalicylic acid (ASA) in patients with high cardiovascular risk.

Material and мethods. Patients (n=30) with high cardiovascular risk and indications for the ASA therapy were included in the study. Antiplatelet agents were withdrawn 3 weeks before study start (wash-out period). Study drugs were distributed at the start visit according to the randomization scheme. The first study drug course was 3 weeks, then next wash-out period lasting 3 weeks, and at last the second study drug course during 3 weeks occurred. Blood samples were taken; blood pressure and heart rate were recorded before and after therapies. ASA antiplatelet effect was evaluated by spontaneous and ADP-induced platelet aggregation assessment. Platelet aggregation was determined by the change turbidimetric translucent ability of the blood sample during the formation of aggregates after 2 minutes of exposure. ADP solution of three concentrations (0.5, 1 and 2 µMol) was used as an inductor of aggregation.

Results. Significant differences between the compared drugs in effect on platelet aggregation, blood pressure and heart rate were not found. Signs of platelet desaggregation after 3 weeks of generic ASA therapy were found in 65, 34.5 and 31% of patients when aggregation was tested with ADP 0.5, 1 and 2 µMol respectively. Desaggregation was revealed in 65.4, 42.3 and 31% of patients treated with original ASA (p>0.05) in the same test and the same ADP inducing concentration.. Adverse events associated with study drugs were not registered.

Conclusion. ASA generic Trombopol ® 75 mg (Pharmaceutical Factory Polpharma SA, Poland) and ASA original Aspirin® Cardio (Bayer AG, Germany) are equivalent in antiplatelet effect and tolerability.

About the Authors

S. Yu. Martsevich
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


S. N. Tolpygina
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


E. S. Boychenko
Polyclinic № 2 of the Central Internal Affairs Directorate for Moscow
Russian Federation
Zatsepa ul.40, Moscow, 115054


R. E. Dubinskaya
Polyclinic № 2 of the Central Internal Affairs Directorate for Moscow
Russian Federation
Zatsepa ul.40, Moscow, 115054


Yu. V. Lukina
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


V. P. Voronina
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


References

1. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1—113.

2. Oganov R.G., Lepakhin V.K., Fitilev S.B. et al. Features of diagnosis and therapy of stable angina in the Russian Federation (International StudyATP-Angina Treatment Pattern). Kardiologiia 2003; 5: 9—15. Russian (Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP–Angina Treatment Pattern). Кардиология 2003; 5: 9–15).

3. Komarov A.L., Panchenko E.L. The role of antithrombotic therapy for prevention of atherosclerosis. Russkiy meditsinskiy zhurnal 2003; 11(19): 1102-1106. Russian (Комаров А.Л., Панченко Е.Л. Значение антитромботической терапии для профилактики атеросклероза. РМЖ 2003; 11(19): 1102—1106).

4. National guidelines for diagnosis and correction of disorders of lipid metabolism in order to prevent and treat atherosclerosis. Kardiovaskulyarnaya terapiya i profilaktika 2007; 6(6) prilozhenie 3:1—32. Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007; 6(6) приложение 3:1-32.

5. Simoons M.L. Cardio-vascular disease in Europe: challenges for the medical profession. Opening address of the 2002 Congress European Society of Cardiology. Eur HeartJ 2003; 24(1): 8—12.

6. Harrington R.A., Becker R.C., Ezekowitz M. et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 513S—548S.

7. Tran H., Anand S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292 (15): 1867—1874.

8. Aronov D.M., Lupanov V.P. Secondary prevention of chronic ischemic heart disease. Lechashchiy vrach 2004; 7: 66—70. Russian (Аронов Д.М., Лупанов В.П. Вторичная профилактика хронической ишемической болезни сердца. Лечащий врач 2004; 7: 66–70).

9. How to develop and implement a national drug policy. Second edition. Geneva: WorldHealth Organization; 2001. Available on: http://apps.who.int/medicinedocs/pdf/s2283e/ s2283e.pdf. Date last accessed: November 31 2010.

10. Maksimkina E. Original drug or generic: an analysis of consumer preferences. Remedium 2000;1-2:74—75. Russian (Максимкина Е. Оригинальный препарат или дженерик: анализ потребительских предпочтений. Ремедиум 2000;1-2: 74-75).

11. Ross-Lee L.M., Elms M.J., Cham B.E. et all. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. EurJ Clin Pharmacol 1982; 23(6): 545—51.

12. Lukina J.V., Deev A.D., Dmitrieva N.A. et al. Comparative study of new drug of long acting metoprolol tartrate — Egilok retard and original drug of metoprolol succinate — Betaloc ZOK in patients with mild to moderate arterial hypertension. Rational Pharmacother Card 2005;3:35—40. Russian (Лукина Ю.В., Деев А.Д.,Дмитриева Н.А. и др. Сравнительное изучение нового препарата метопролола тартрата пролонгированного действия эгилока ретард и оригинального препарата метопролола сукцината беталока ЗОК у больных мягкой и умеренной артериальной гипертонией. РФК 2005;1(3):35-40).

13. Meshkovskiy A.P. Place of a generic in drug provision. Farmateka 2003; 3:103—108. Russian (Мешковский А.П. Место дженериков в лекарственном обеспечении. Фарматека 2003; 3:103-108).

14. Martsevich S.Yu., Kutishenko N.P., Deev A.D. et al. The study of the therapeutic equivalence of two drugs amlodipine (the original and reproduced) in hypertensive patients. The results of a randomized double-blind crossover study. Rossiyskiy kardiologicheskiy zhurnal 2004;4:53—57. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д. и др. Изучение терапевтической эквивалентности двух препаратов амлодипина (оригинального и воспроизведенного) у больных артериальной гипертонией. Результаты двойного слепого рандомизированного перекрестного исследования. РКЖ 2004;4:53—57.

15. Nedogoda S.V., Marchenko I.V., Chalyabi T.A. Comparative antihypertensive efficacy of generic ACE inhibitor enalapril - Renitek (Enap, Ednit, Invoril, Envas and Enam) and the cost of treatment in patients with hypertension. Arterial'naya gipertenziya 2000;1:52— 54. Russian (Недогода С.В., Марченко И.В., Чаляби Т.А. Сравнительная антигипертензивная эффективность дженериков ингибитора ангиотензин-превращающего фермента эналаприла-ренитека (энапа, эднита, инворила, энваса и энама) и стоимость лечения у больных гипертонической болезнью. Артериальная гипертензия 2000;1:52— 54).

16. Carter B.L., Noyes M.A., Demmler R.W. Differences in serum concentrations and response to generic verapamil in the elderly. Pharmacotherapy 1993;13(4):359—368.

17. Martsevich S.Y., Lukina J.V., DeevA.D. et al. Comparative study of combined drugs of enalapril maleate and hydrochlorothiazide: «Renipril HT» and «Co-renitec» in patients with mild to moderate arterial hypertension. Rational Pharmacother Card 2005; 3:29-34. Russian (Марцевич С.Ю., Лукина Ю.В., Деев А.Д. и др. Сравнительное изучение комбинированных препаратов эналаприла малеата и гидрохлортиазида: «рениприла ГТ» и «ко-ренитека» у больных мягкой и умеренной АГ. РФК 2005;1(3):29—34).

18. Ruda M.Ya., ed. Antiplatelet therapy with acetylsalicylic acid. Pharmacokinetics. M.: Meditsina; 1998. Russian (Руда М.Я., редактор. Антитромбоцитарная терапия ацетилсалициловой кислотой. Фармакокинетика. М.: Медицина; 1998).

19. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308(6921): 81—106.

20. Cham B.E., Ross-Lee L., Bochner F., Imhoff D.M. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit 1980;2(4):365—371.

21. Dubovská D., Piotrovskij V.K., Gajdos M. et al. Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling. Methods Find Exp Clin Pharmacol 1995;17(1):67—77.

22. Edgar B., Bogentoft C., Lagerström P.O. Comparison of two enteric-coated acetylsalicylic acid preparations by monitoring steady-state levels of salicylic acid and its metabolites in plasma and urine. Biopharm Drug Dispos 1984;5(3):251—60.

23. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6):1105—1187.

24. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1988; 351(9118): 1762—66.

25. Peto R., Buring J., Hennekens C. et al. Antitrombotic Trialists (ATT) Collaboration. Aspirin in primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373(9678):1849—1860.

26. Cerletti C., Dell'Elba G., Manarini S. et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003;42(12):1059—70.

27. Taylor D.W., Barnett H.J., Haynes R.B. et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomized controlled trial. ASAand Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999;353:2179—84.


For citation:


Martsevich S.Y., Tolpygina S.N., Boychenko E.S., Dubinskaya R.E., Lukina Y.V., Voronina V.P. COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR). Rational Pharmacotherapy in Cardiology. 2010;6(6):796-802. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-796-802

Views: 267


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)